Can a pill prevent eye cancer spread? new trial aims to find out
NCT ID NCT06932757
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the drug quisinostat can prevent uveal melanoma from spreading in high-risk patients. About 63 people who have completed initial treatment for their eye tumor will take quisinostat capsules three times a week. Researchers will track how long participants stay free of distant metastases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Quisinostat (a drug taken as a capsule three times a week)
- What this could lead to
- If it works, this could help prevent uveal melanoma from spreading to other parts of the body in high-risk patients.
- What could go wrong
- This is a small, early-phase trial with only 63 participants. The drug may not prevent metastasis, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug tame advanced solid tumors?
- Can a single eye injection shrink melanoma and save sight?
- Supercharged immune cells take aim at childhood cancers
- New drug shows promise in shrinking eye cancer before surgery
- 500 eye melanoma patients share their quality of life journey